Medical tech company spun off from National University of Singapore hits B round.

Clearbridge BioMedics, medical tech company spun off from National University of Singapore, has raised SG$9m ($7.2m) in its series B round.

Vertex Venture, a venture capital subsidiary of Singapore state-owned investment company Temasek, led the B round, which also included VC firm BioVeda Capital, the government’s co-funding scheme, Spring Seeds Capital, Clearbridge Biomedical Sciences Accelerator, a wholly-owned SG$40m investment subsidiary of Clearbridge Accelerator (CBA), and Lu Yoh Chie, Biosensors International founder and existing shareholder.

Clearbridge BioMedics uses its CTChips system to detect, isolate, and retrieve tumour cells from blood samples.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?